<DOC>
	<DOCNO>NCT01459185</DOCNO>
	<brief_summary>The investigator confirm feasibility 1-year administration oral fluoropyrimidine S-1 adjuvant chemotherapy patient receive complete resection non-small cell lung cancer . The investigator presume achieve high completion rate low toxicity .</brief_summary>
	<brief_title>A Feasibility Study Oral Adjuvant Chemotherapy With S-1</brief_title>
	<detailed_description>Chemotherapy comprise eight course ( 4-week administration , 2-week withdrawal ) S-1 ( FT , gineracil , oteracil potassium ; Taiho Pharmaceutical , Tokyo , Japan ) 80-120 mg/body/day accord body surface area ( BSA ) : BSA &lt; 1.25 m2 , 80 mg/day ; BSA &gt; 1.25 m2 &lt; 1.5 m2 , 100 mg/day ; BSA &gt; 1.5 m2 , 120 mg/day . S-1 administer orally , twice daily meal , start within 4 week surgery .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<criteria>1 . NSCLC histological proof . 2 . Pathological stage IB , II , IIIA NSCLC ( fifth edition UICC/AJCC 1997 ) complete resection . 3 . No prior treatment except surgery . 4 . Sufficient oral intake . 5 . Performance status ( PS ) 0 1 . 6 . Patients also adequate organ function ( 3500 &lt; leukocytes &lt; 12,000/mm3 ; thrombocyte , &gt; 100,000/mm3 ; total bilirubin , &lt; 1.5 mg/dl ; AST ALT , less twice normal limit institution ; BUN , &lt; 25 mg/dl ; creatinine , less normal limit institution ; creatinine clearance ( Ccr ) ) 1 . History drug hypersensitivity . 2 . Contraindication oral S1 administration ( refer append paper ) . 3 . Serious surgical nonsurgical complication 4 . Active secondary cancer . 5 . Watery diarrhea . 6 . Pregnant lactating woman . 7 . Male intention make pregnant 8 . Patient primary doctor judge inadequate register .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Non-small cell lung cancer</keyword>
	<keyword>Adjuvant chemotherapy</keyword>
	<keyword>oral fluoropyrimidine</keyword>
	<keyword>S-1</keyword>
	<keyword>Feasibility study</keyword>
	<keyword>Surgery</keyword>
</DOC>